Related Experiment Videos
Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical
R H Williams1, A M Stapleton, G Yang
1Scott Department of Urology and Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA.
Abstract:
In previous studies we demonstrated that the growth of human prostatic adenocarcinoma is associated with aberrant accumulation of transforming growth factor (TGF) beta1, a growth factor that has been shown to be a potent inhibitor of epithelial cell proliferation. We investigated the expression of TGF-beta receptor II (TGFbetaR-II) in benign prostate tissue and in prostate cancer using standard immunohistochemical techniques. Quantitation of immunopositivity for TGFbetaR-II was assessed on a visual analogue scale ranging from 0 (absence of staining) to 4+ (intensely positive staining). All of the benign glandular epithelia stained intensely, either 3+ or 4+, representative of the ubiquitous nature of TGFbetaR-II in normal tissue. Overall, staining was reduced in prostate cancer sections, and there was progressively diminished staining as the histological grade of the cancer increased (P < 0.01, Kruskal-Wallis test). This immunohistochemical study indicates that a decline in the levels of TGFbetaR-II is correlated with advancing histological aggressiveness of the cancer and suggests that aberrant TGFbetaR-II function may play a role in human prostate carcinogenesis.
Insights
Prostate cancer growth is linked to transforming growth factor (TGF) beta1. This study found reduced expression of the TGF-beta receptor II (TGFbetaR-II) in prostate cancer, correlating with increased cancer aggressiveness.
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- Prostate adenocarcinoma growth is associated with transforming growth factor (TGF) beta1 accumulation.
- TGF-beta1 is a potent inhibitor of epithelial cell proliferation.
- The role of TGF-beta receptor II (TGFbetaR-II) in prostate cancer is not fully understood.
Purpose of the Study:
- To investigate the expression of TGFbetaR-II in benign prostate tissue and prostate cancer.
- To correlate TGFbetaR-II expression levels with the histological grade of prostate cancer.
Main Methods:
- Standard immunohistochemical techniques were used to assess TGFbetaR-II expression.
- Immunopositivity was quantified using a visual analogue scale (0-4+).
- Statistical analysis (Kruskal-Wallis test) was performed to evaluate correlations.
Main Results:
- Benign prostate epithelia showed intense TGFbetaR-II staining (3+ or 4+).
- Prostate cancer sections exhibited reduced TGFbetaR-II staining compared to benign tissue.
- A significant inverse correlation was observed between TGFbetaR-II levels and histological grade (P < 0.01).
Conclusions:
- Decreased TGFbetaR-II levels correlate with increased histological aggressiveness in prostate cancer.
- Aberrant TGFbetaR-II function may contribute to prostate carcinogenesis.
- TGFbetaR-II is a potential biomarker for prostate cancer progression.